Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > COMMENTARY
COMMENTARY
- OPINION／The East versus West Dilemma
January 28, 2008
- No More Need for MRs？ -A Hell beyond the 2010 Crisis？-
January 14, 2008
- COMMENTARY／Year 2007 in Retrospect
December 24, 2007
- COMMENTARY／Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
- COMMENTARY／Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
- COMMENTARY：Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
- Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
- COMENTARY：Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
- COMMENTARY／NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
- COMMENTARY／Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
- COMMENTARY／Market for Osteoporosis Drugs Booms
July 9, 2007
- COMMENTARY／Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
- COMMENTARY：Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply
June 25, 2007
- COMMENTARY／Provisional Deliveries without Agreement on Prices
June 11, 2007
- COMMENTARY／Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
- COMMENTARY／Korosho to Consider Introduction of CU System
May 28, 2007
- Explosion of Shin-Etsu Chemical's Cellulose Production PlantGood Opportunity to Reconsider Raw Material Procurement System
April 30, 2007
- COMMENTARY／Japan Moves toward Affiliation with PIC/S
April 23, 2007
- COMMENTARY／India Attracts Increasing Attention of Japanese Pharmas
April 16, 2007
- COMMENTARY：Growing Market for Biopharmaceuticals
April 2, 2007
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…